The MEIP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MEIP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The MEIP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View MEIP Detailed Price Forecast - CNN Money||View MEIP Detailed Summary - Google Finance|
|View MEIP Detailed Summary - Yahoo! Finance||View MEIP Stock Research & Analysis - Zacks.com|
|View MEIP Trends & Analysis - Trade-Ideas||View MEIP Major Holders - Barrons|
|View MEIP Call Transcripts - NASDAQ||View MEIP Breaking News & Analysis - Seeking Alpha|
|View MEIP Annual Report - CompanySpotlight.com||View MEIP OTC Short Report - OTCShortReport.com|
|View MEIP Fundamentals - TradeKing||View MEIP SEC Filings - Bar Chart|
|View Historical Prices for MEIP - The WSJ||View Performance/Total Return for MEIP - Morningstar|
|View the Analyst Estimates for MEIP - MarketWatch||View the Earnings History for MEIP - CNBC|
|View the MEIP Earnings - StockMarketWatch||View MEIP Buy or Sell Recommendations - MacroAxis|
|View the MEIP Bullish Patterns - American Bulls||View MEIP Short Pain Metrics - ShortPainBot.com|
|View MEIP Stock Mentions - StockTwits||View MEIP Stock Mentions - PennyStockTweets|
|View MEIP Stock Mentions - Twitter||View MEIP Investment Forum News - Investor Hub|
|View MEIP Stock Mentions - Yahoo! Message Board||View MEIP Stock Mentions - Seeking Alpha|
|View Insider Transactions for MEIP - SECform4.com||View Insider Transactions for MEIP - Insider Cow|
|View MEIP Major Holdings Summary - CNBC||View Insider Disclosure for MEIP - OTC Markets|
|View Insider Transactions for MEIP - Yahoo! Finance||View Institutional Holdings for MEIP - NASDAQ|
|View MEIP Stock Insight & Charts - FinViz.com||View MEIP Investment Charts - StockCharts.com|
|View MEIP Stock Overview & Charts - BarChart||View MEIP User Generated Charts - Trading View|
MEI Pharma To Present at Two Upcoming Investor Conferences
Posted on Wednesday March 14, 2018
A live audio webcast of each event can be accessed on the Events & Presentations page of the Investors section of MEI Pharma's website at http://www.meipharma.com, or by following the links below in your web browser. An archived replay of each webcast will be available on MEI Pharma's website for at least 30 days after the live event concludes. MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer.
MEI Pharma Appoints Industry Veteran Frederick W. Driscoll to its Board of Directors
Posted on Monday February 26, 2018
SAN DIEGO, Feb. 26, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the appointment of Frederick W. Driscoll to its board of directors. Mr. Driscoll will serve on the audit committee. "As an industry veteran, Fred brings MEI a tremendous amount of industry and financial experience that we can leverage to effectively advance our oncology pipeline as our programs move into later stage development," said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma.
MEI Pharma Interim Data Review Supports Continuation of Clinical Study Evaluating ME-344 in Patients with Breast Cancer
Posted on Tuesday February 13, 2018
SAN DIEGO, Feb. 13, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that a planned interim review of data supports continuation of its multicenter, investigator sponsored, study evaluating ME-344, a novel mitochondrial inhibitor, in patients with HER2-negative breast cancer. The interim study data show that ME-344 was generally well-tolerated and, consistent with previous preclinical data, demonstrate the potential to reverse resistance to antiangiogenic therapy. Based on the interim results, it was determined that completion of enrollment of the clinical study of ME-344 in combination with bevacizumab (marketed as Avastin®) is warranted.
MEI Pharma Reports Second Quarter Fiscal Year 2018 Results
Posted on Thursday February 08, 2018
Pipeline advancement continues, including clearance of voruciclib IND by FDA and pracinostat Orphan Drug Designation by EMA Data readouts in three programs expected in the second quarter of 2018 SAN DIEGO ...